Isotopes of ytterbium

ASP Isotopes Issues Letter to Stockholders

Retrieved on: 
木曜日, 4月 11, 2024
Consensus, FDA, Nuclear energy, Uranium, Memorandum, Void coefficient, SMR, Intelligence, Prostate cancer, Isotope, ASP, Silicon, Annual report, Yoy, PET, Semiconductor, Private, DOE, Acceleration, Safety, GE HealthCare, Small modular reactor, Artificial intelligence, Coal, Nuclear Energy Institute, Exercise, Isotopes of ytterbium, NEI, Cyclotron, Laser, Radiopharmaceutical, Government, FDG, Silane, Sale, Lithium, Lutetium (177Lu) vipivotide tetraxetan, LEU, Lutetium, Radionuclide, Electronics, ASPI, Letter, Growth, Rare-earth element

WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.

Key Points: 
  • WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASPI,” or the “Company”), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries, today released the following letter to stockholders from its Chairman and CEO, Paul Mann.
  • The contract required RC14 to provide an irrevocable standby letter of credit in lieu of a deposit, which was received.
  • Our proprietary technology has proven capabilities to enrich a wide range of isotopes, including light isotopes and lighter molecules, such as silane (SiH4).
  • ASP Isotopes’ goal is to become the lowest cost and most reliable supplier of stable isotopes globally.

ITM: Installation of New Isotope Production System at Bruce Power to Produce Medical Isotopes for Cancer Therapy Completed

Retrieved on: 
月曜日, 1月 24, 2022
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, III, Electricity, Patient, Ministry of Agriculture, Food and Rural Affairs (Ontario), MPP, Saugeen Ojibway Nation Territory, Power, ITM, LinkedIn, Prostate cancer, Saugeen First Nation, OMERS, Isotope, CEO, Physician, Cancer, Leadership, Instagram, Wilms' tumor, Sound, Private, Society, YouTube, IPS, Environment, Investment, Bruce—Grey—Owen Sound, Radionuclide, Chippewas of Nawash Unceded First Nation, Huron—Bruce, Bruce Power, Food, Nuclear medicine, Twitter, TC Energy, CANDU, SON, Partnership, Nuclear Deterrence Operations Service Medal, Medical imaging, Lithium, Renewable energy, Energy, Isotopes of ytterbium, Agriculture, Ojibwe, Isogenic human disease models, Facebook, Framatome, ITM Isotope Technologies Munich SE, Bruce Power, Isogen, ITM ISOTOPE TECHNOLOGIES MUNICH SE, BRUCE POWER, ISOGEN

This system will also have the ability to produce other isotopes for medical uses over the long term.

Key Points: 
  • This system will also have the ability to produce other isotopes for medical uses over the long term.
  • Ontario is leading the way in the production and supply of medical isotopes around the world, said Hon.
  • Im proud of the innovative work being done by Bruce Power and its partners in the supply chain, including Framatome and Kinectrics.
  • Isogens enabling partnerships with Bruce Power and ITM allows us to produce the worlds largest and most reliable supply of life-saving, short-lived, therapeutic medical isotopes.

POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177

Retrieved on: 
金曜日, 10月 29, 2021
Bruce Power, Engineering, Chemistry, Physics, Hospital, Cancer, Industry, MCRPC, Certification, Actinium-225, Radionuclide, Graphite-moderated reactor, Patient, Private Securities Litigation Reform Act, NASDAQ, Radiopharmaceutical, Terminology, SEC, Nuclear physics, Risk, Biopharma LLC, Forward-looking statement, Heinkel He 112 operational service, Investment, Electricity, Intention, CEO, COVID-19, Growth, SPLASH, Program, Laboratory, Isotopes of ytterbium, Prostate cancer, GLOBE, Rare-earth element, Medical imaging, Lithium

INDIANAPOLIS and TORONTO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, and Kinectrics Inc., a leading service provider to the nuclear power and electricity industry, announced today a long-term supply agreement for Ytterbium-176 (Yb-176) to support POINT’s in-house no-carrier added Lutetium-177 (n.c.a. Lu-177) production program.

Key Points: 
  • With this agreement with Kinectrics, POINT is laying the groundwork to access large quantities of highly enriched Yb-176, creating the worlds first, stable North American supply of n.c.a.
  • Ensuring a secure, redundant and consistent isotope supply is a cornerstone of POINTs radiopharmaceutical platform, said Dr. Joe McCann, CEO of POINT Biopharma.
  • Kinectrics deep experience in nuclear physics and engineering makes them an ideal partner to supply stable isotope precursor for our manufacturing processes.
  • Creating a North American supply of Yb-176 is critical to safeguard the supply-chain for Lu-177, said David Harris, CEO of Kinectrics.